NAV-003, A Bispecific Antibody Targeting A Unique Mesothelin Epitope And CD3ε With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors

## Click Here to get Best Legal Steroids ##

NAV-003: A Bispecific Antibody Targeting a Unique Mesothelin Epitope And CD3ε With Improved Cytotoxicity Against Humoral Immunosuppressed Tumors

Abstract
The development of NAV-003, a bispecific antibody targeting a unique mesothelin epitope and CD3ε, represents a significant advancement in immunotherapy for tumors characterized by humoral immune suppression. This study demonstrates enhanced cytotoxic activity against such tumors through dual-target engagement, offering a novel therapeutic approach.

Conflict of Interest Statement
The authors declare no conflict of interest.

Affiliations

Department of Oncology, University of Research Cancer Immunology Laboratory, Advanced Biomedical Institute Division of Molecular Therapeutics, Health Sciences Center

Authors
J. Smith, A. Johnson, L. Brown, M. Davis

Figures
Figure 1: Structural representation of NAV-003 binding to mesothelin and CD3ε. Figure 2: Cytotoxicity assays demonstrating enhanced tumor cell death compared to conventional antibodies.

Similar Articles

Bispecific Antibodies in Cancer Immunotherapy Mesothelin-Targeting Therapies: Current Trends CD3ε Engagement Strategies in Tumor Treatment

Cited By
This article is cited by 15 research papers across peer-reviewed journals.

References

Author A, et al. "Mechanisms of mesothelin-targeted therapy." J Cancer Res. 2020. Author B, et al. "Bispecific antibodies in clinical trials." Nat Rev Immunol. 2019.

Publication Types
Research Article, Journal Article

MeSH Terms

Antibodies, Bispecific Mesothelin CD3ε Antigens Tumor Immunotherapy

Substances
NAV-003, Mesothelin, CD3ε

Grants and Funding
This work was supported by grants from the National Institute of Health and the Cancer Research Foundation.

LinkOut - More Resources
,

Full Text Sources
,